The use of prophylactic heparin in cancer

ISSN: 2147-0634
Yayın Aralığı: 4
Başlangıç: 2012
Yayıncı: Effect Publishing Agency ( EPA )

___

Qureshi W, Ali Z, Amjad W, et al. venous thromboembolism in cancer: an update of treatment and prevention in the era of newer anticoagulants. Front Cardiovasc Med. 2016;3:24.

Guy JB, Bertoletti L, Magné N, et al. Venousthromboembolismin radiation therapy cancer patients: Findings from the RIETE registry. Crit Rev Oncol Hematol. 2017;113:83-9.

Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22:1944-8.

Schünemann HJ, Ventresca M, Crowther M et al. Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. BMJ Open. 2016;6:e010569.

Borsin L, Wong R, Feramisco J, et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci. 2001;98:3352-7.

Lee AY, Levine MN, Baker RI, et al. Randomized comparison of low molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent ve n o u s thromboembolism in patients with cancer (CLOT) investigators. low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:14653.

Borsig L. Heparin as an inhibitor of cancer progression. Prog Mol Biol Transl Sci. 2010;93:335-49.